VIRX - Viracta Therapeutics, Inc. Stock Price, Fair Value and News

$0.210.00 (0.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VIRX Price Action

Last 7 days

Last 30 days

40%

Last 90 days

-4.5%

Trailing 12 Months

-57.1%

VIRX RSI Chart

VIRX Valuation

Market Cap

8.3M

Price/Earnings (Trailing)

-0.19

Price/Sales (Trailing)

Price/Free Cashflow

-0.18

VIRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VIRX Fundamentals

VIRX Revenue

Revenue (TTM)

2.8M

Rev. Growth (Yr)

-62.27%

Rev. Growth (Qtr)

-58.51%

VIRX Earnings

Earnings (TTM)

-43.3M

Earnings Growth (Yr)

16.25%

Earnings Growth (Qtr)

-7.36%

VIRX Profitability

Return on Equity

654.21%

Return on Assets

-197.14%

Free Cashflow Yield

-549.36%

VIRX Investor Care

Shares Dilution (1Y)

2.90%

Diluted EPS (TTM)

-1.1

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	2.8M	0
2023	0	2.0M	2.8M	3.1M
2022	42.0K	80.0K	544.0K	1.2M
2021	45.5K	43.0K	40.5K	38.0K
2020	58.0K	54.6K	51.3K	48.0K
2019	0	0	0	61.3K
2018	237.0K	237.0K	237.0K	237.0K
2017	2.6M	2.0M	1.3M	669.0K
2016	2.8M	2.6M	2.5M	2.5M
2015	4.6M	3.5M	3.3M	3.1M
2014	8.0M	8.0M	6.8M	5.7M
2013	5.7M	6.2M	8.0M	8.0M
2012	0	2.5M	2.8M	3.8M
2011	4.5M	4.6M	4.8M	5.0M
2010	0	3.9M	4.1M	4.3M
2009	0	0	0	3.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor; and VRx-510, a preclinical-stage PDK-1 inhibitor. The company was formerly known as Sunesis Pharmaceuticals, Inc. and changed its name to Viracta Therapeutics, Inc. in February 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.

CEO	Mr. Mark Andrew Rothera
WEBSITE	viracta.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	41

Viracta Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Viracta Therapeutics, Inc.? What does VIRX stand for in stocks?

VIRX is the stock ticker symbol of Viracta Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Viracta Therapeutics, Inc. (VIRX)?

As of Fri Dec 20 2024, market cap of Viracta Therapeutics, Inc. is 8.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VIRX stock?

You can check VIRX's fair value in chart for subscribers.

Is Viracta Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether VIRX is over valued or under valued. Whether Viracta Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Viracta Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIRX.

What is Viracta Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, VIRX's PE ratio (Price to Earnings) is -0.19 and Price to Sales (PS) ratio is 3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VIRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Viracta Therapeutics, Inc.'s stock?

In the past 10 years, Viracta Therapeutics, Inc. has provided -0.543 (multiply by 100 for percentage) rate of return.